Since there were differences in AD biomarker trajectories depending on sex and APOE genotype, our findings will help to design individualized therapeutic and preventive strategies to ameliorate AD biomarkers, resulting in cognitive decline. This evidence concerns the gene APOE and Alzheimer disease.